ALTASCIENCES
Altasciences , a mid-size CRO specializing in a flexible, innovative approach to providing comprehensive early stage drug development from lead candidate selection to proof of concept, today announced that it has acquired Alliance Contract Pharma . This acquisition adds small molecule contract manufacturing and analytical services from API to commercialization, including commercial manufacturing, GMP warehouse storage, and clinical supply distribution, to Altasciences’ full-service preclinical, clinical, and bioanalytical offerings.
Transferring data, projects, and/or methodologies between CROs, or between different groups within a multi-service CRO, takes time, is prone to error, and can lead to prolonged R&D timelines. Altasciences is addressing these challenges through the integration of key strategic additions, such as their preclinical business in October 2018 , and now Alliance Contract Pharma. Clients partnering with Altasciences on their drug development programs benefit from working with a fully integrated CRO, allowing for quicker, more proactive development timeline adjustments and decision making to improve R&D efficiency.
“The addition of Alliance Contract Pharma continues to fulfill our strategy of creating a comprehensive offering that facilitates the outsourcing experience for our clients. We remain committed to providing our clients with value-added services that create a new paradigm of drug development outsourcing,” added Chris Perkin, CEO of Altasciences.
“We are excited to be joining a team that is responsive and understanding, and continuously looking to create innovative partnerships that redefine the status quo and address the challenges that our clients face in meeting critical milestones, ” stated Stephen Schweibenz, President of Alliance Contract Pharma.
BlackArch Partners served as exclusive financial advisor to Alliance Contract Pharma.
About Altasciences
Altasciences is a forward-thinking, mid-size contract research organization offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200227005731/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Coolbrook Named on the 2026 Global Cleantech 10015.1.2026 18:14:00 CET | Press release
Coolbrook, a transformational technology and engineering company on a mission to decarbonise major industrial sectors like petrochemicals and chemicals, iron and steel, aluminium, and cement, has been named on Cleantech Group’s 2026 Global Cleantech 100. This annual list recognizes companies poised to deliver market-ready solutions that advance a cleaner, more resilient global future. The report highlights innovators addressing some of the world’s most urgent environmental and infrastructure challenges. The complimentary report introduces you to innovators advancing groundbreaking technologies and business models to enable us to act on the ever-increasing climate and environmental crisis. Following a 2025 marked by geopolitical volatility and shifting economic signals, the global cleantech ecosystem enters 2026 with slightly greater certainty - yet heightened competitive pressure. Growth is concentrating around two dominant themes: AI infrastructure and critical minerals. “The 2026 Glo
Frasca to Supply Four New Flight Training Devices to Global Medical Response15.1.2026 16:05:00 CET | Press release
New Level 7 FTDs will support pilot training for emergency medical operations Frasca International, Inc., a FlightSafety International company, today announced it has signed a contract with Global Medical Response (GMR) to supply four new Level 7 Flight Training Devices (FTDs). The new devices include an Airbus EC135, a Pilatus PC-12, a Beechcraft C90, and a Beechcraft B200. Each FTD will feature Frasca's unique motion system to provide enhanced realism in training. The devices will be installed at GMR’s new training facility currently under construction in Denton, Texas. Frasca has supported GMR’s pilot training efforts for nearly two decades, beginning with the delivery of their first device in 2005 for Air Evac Lifeteam, a GMR company. Since then, Frasca simulators have played a central role in preparing GMR’s flight crews for the complex and high-stakes environments they encounter in emergency medical operations. With the delivery of these new devices, GMR will operate a total of 1
illumynt Reports 60% Revenue Growth and Launches Global Innovation Center to Meet Rising Enterprise Security and Sustainability Demands15.1.2026 15:11:00 CET | Press release
illumynt an intelligent, security-first technology lifecycle partner, today announced significant growth and innovation milestones that position the company as a leader in the next evolution of the IT Asset Disposition (ITAD) industry—an industry increasingly shaped by artificial intelligence, accelerated hardware refresh cycles, and heightened regulatory scrutiny. Under the leadership of CEO Joerg Herbarth, illumynt continues to execute its mission to deliver intelligent, technology-driven lifecycle solutions that maximize sustainability, security, and recovery value for the world’s most compute-intensive organizations. In 2025, ITAD became a strategic imperative. AI-driven workloads have dramatically compressed infrastructure lifecycles, while updates to NIST SP 800-88 Rev. 2, adoption of R2v3, and the expansion of global privacy frameworks have raised expectations for auditability, transparency, and verified data security. As a result, ITAD has evolved from a back-end operational fu
Rimini Street Wins Multiple Industry Awards Recognizing AI Innovation, Client-First Culture, Technical Excellence and Business Impact15.1.2026 15:00:00 CET | Press release
Accolades include Tech Ascension Award for AI-Powered Agent Solution of the Year, Top Tech of the Year Award (Las Vegas), Silver Globee Award in the Customer Service Team of the Year Category and Women Leading IT Award for client, Hitachi Vantara Rimini Street, Inc., (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™, and the leading third-party support provider for Oracle, SAP and VMware software, has been recognized by top industry award programs for its innovation, technical excellence and client-first culture. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115632021/en/ Rimini Street Wins Multiple Industry Awards Recognizing AI Innovation, Client-First Culture, Technical Excellence and Business Impact Winner of the AI-Powered Enterprise (Agent) Solution of the Year Category for Fueling Innovation and Driving Business Outcomes Rimini Street earned a 2025 Tech Ascension Award in the AI-powered Enterprise (
Lone Star Announces Sale of SENQCIA to Noritsu Koki15.1.2026 14:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XI, L.P. has entered into a definitive agreement to sell SENQCIA Corporation (“SENQCIA”), a leading provider of mission-critical building products and solutions in Japan, to Noritsu Koki Co., Ltd., in a transaction that represents a total enterprise value of approximately $519 million. Headquartered in Tokyo, SENQCIA develops, designs and distributes essential structural solutions that enhance the resilience, integrity and long-term safety of buildings and infrastructure. The company’s diversified product portfolio serves a broad range of end-markets and property types that are used in many iconic landmark properties across Japan. SENQCIA’s solutions help address key structural challenges facing Japan, including increasing natural disaster risk and aging infrastructure and building stock. During Lone Star’s ownership, SENQCIA has enhanced its go-to-market strategy and reinforced its operational resilience
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom